Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants

Functional gastrointestinal disorders (FGIDs) are a common concern during the first year of life. Recognized as gut-brain axis disorders by Rome IV criteria, FGIDs etiology is linked to altered gut-brain interaction, intestinal physiology, and microbiota. In this regard, probiotics have emerged as a promising therapy for infant FGIDs. In this study, we have investigated the probiotic potential of the strains Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041—isolated from healthy children’s feces—in the treatment of FGIDs. To this scope, genome sequences of both strains were obtained and subjected to in silico analyses. No virulence factors were detected for any strain and only the non-transferable erm(49) gene, which confers resistance to erythromycin and clindamycin, was identified in the genome of B. longum KABP042. Safety of both strains was confirmed by acute oral toxicity in rats. In vitro characterization revealed that the strains tolerate gastric and bile challenges and display a great adhesion capacity to human intestinal cells. The two strains mediate adhesion by different mechanisms and, when combined, synergically induce the expression of Caco-2 tight junction proteins. Moreover, growth inhibition experiments demonstrated the ability of the two strains alone and in combination to antagonize diverse Gram-negative and Gram-positive bacterial pathogens during sessile and planktonic growth. Pathogens’ inhibition was mostly mediated by the production of organic acids, but neutralization experiments strongly suggested the presence of additional antimicrobial compounds in probiotic culture supernatants such as the bacteriocin Lantibiotic B, whose gene was detected in the genome of B. longum KABP042. Finally, an exploratory, observational, pilot study involving 36 infants diagnosed with at least one FGID (infant colic and/or functional constipation) showed the probiotic formula was well tolerated and FGID severity was significantly reduced after 14 days of treatment with the 2 strains. Overall, this work provides evidence of the probiotic and synergic properties of strains B. longum KABP042 and P. pentosaceus KABP041, and of their potential to treat pediatric FGIDs.Clinical Trial Registration: [www.ClinicalTrials.gov], [identifier NCT04944628].

Fonksiyonel Gastrointestinal Bozukluklarda Beslenmenin Önemi ve Diyetisyenin Rolü

Fonksiyonel gastrointestinal bozukluklar (FGID-functional gastrointestinal disorders) herhangi bir organik bozukluk olmamasına karşın kronik veya tekrarlayan gastrointestinal semptomlara verilen genel bir addır. Bu bozukluklarda diyetin, hastaya özel olarak hazırlanması ve sürekli izlenmesi çok büyük önem taşımaktadır. Bu süreçte, hastanın beslenme alışkanlıklarının deneyimli diyetisyenler tarafından belirlenmesi ve hasta ile karşılıklı olarak tüm biyo-psiko-sosyal yönler dikkate alınarak incelenmesi, buna göre kişiye özel beslenme ve diyet planının tanzim edilmesi gerekmektedir. FGID’ler arasında en yaygın semptomlar bütünü IBS (Irritable Bowel Syndrome-huzursuz bağırsak sendromu) olarak adlandırılan bozukluktur. IBS’lerde diyetisyenin rolü diğer FGID’lere göre daha da önemli ve özeldir. Türkiye’de diyetisyenlerin bu bozukluklar alanında uzmanlaşması için gerekli adımlar ivedilikle atılmalı ve sağlık kurumlarında diyetisyen kadrosu istihdamı da arttırılmalıdır.

Phytochemical, Pharmacognostic and Pharmacological Studies on Zingiber Officinale

Rhizomes of Zingiber officinale Roscoe. belonging to the family Zingiberaceae is used for bronchitis, as a carminative, for treating cough, cataracts and as a stimulant. The rhizome is cooked with salt and water and used as an expectorant. Extract of the juice of rhizome is used as eye-drops. In Yemen, it is mixed with other plants used for constipation, as a purgative, against colds, catarrh and acidity of the stomach. Root ginger is widely used for culinary purposes and as a spice. The rhizomes (imported from India) are used with cinnamon and cloves and made into a tea for treating colds and as a general tonic. The drink is also used as an aphrodisiac (Gazanfar, 1994). Ginger is useful in piles, rheumatism, headache, lumbago, pains, bleeding, chest congestion, cholera, cold, diarrhea, dropsy, nausea, stomachache, gastrointestinal disorders, vomiting, and diarrhea. The fresh juice of ginger acts as a strong diuretic. The juice of the leaves is effective against helminthiasis and marasmus and related conditions of diarrhea and dysentery (Monograph of Unani Medicine,2003).

A Narrative Review on the Update in the Prevalence of Infantile Colic, Regurgitation, and Constipation in Young Children: Implications of the ROME IV Criteria

Regurgitation, colic, and constipation are frequently reported Functional Gastrointestinal Disorders (FGIDs) in the first few years of life. In 2016, the diagnostic criteria for FGIDs were changed from ROME III to ROME IV. This review assesses the prevalence of the most frequent FGIDs (colic, regurgitation and constipation) among children aged 0–5 years after the introduction of the later criteria. Articles published from January 1, 2016 to May 1, 2021 were retrieved from PubMed and Google Scholar using relevant keywords. A total of 12 articles were further analyzed based on the inclusion and exclusion criteria. This review consists of two studies (17%) from the Middle East, three (25%) from Asia, two (17%) from the USA, three (25%) from Europe, and one (8%) from Africa. Three studies (25%) were based on data obtained from healthcare professionals, while the rest were parent or caregiver reports. About half of the retrieved studies used the ROME IV criteria. Among infants aged 0–6 months, the reported prevalence of colic ranged between 10–15%, whilst that of regurgitation was 33.9%, and constipation was 1.5%. Among infants aged 0–12 months, the reported prevalence of regurgitation and constipation were 3.4–25.9% and 1.3–17.7%, respectively. The reported prevalence of constipation was 1.3–26% among children aged 13–48 months and 13% among children aged 4–18 years. Despite the large variations due to differences in diagnostic criteria, study respondents and age group, the prevalence of infantile colic was higher, while that for infantile regurgitation and constipation were similar using the ROME IV or III criteria.